Morgan Stanley initiated coverage of BioAge Labs (BIOA) with an Overweight rating and $40 price target Initial data for the company’s azelaprag “have been promising,” suggesting it has the potential to increase weight loss in combination with GLP-1s, while improving body composition and weight loss quality, the analyst tells investors in a research note. The firm says early data indicate that azelaprag results in weight loss while having a benefit on muscle.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BIOA:
- BioAge Labs initiated with a Buy at Jefferies
- Opening Day: Self-driving startup Pony.ai files for U.S. IPO
- Arcadium confirms Rio approach, Apollo funds to acquire Barnes: Morning Buzz
- Obesity drugmaker Rivus to weigh IPO as soon as this year, Bloomberg says
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
